Compare Natera Inc. Common Stock (NTRA) vs Nu Holdings Ltd (NU) Price & Performance

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.

NU Holdings (NU) trades at $15.58, down 2.69% on the day, as the stock consolidates near key technical levels. The company demonstrates strong fundamental momentum with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income turning positive to $2.9B. Recent news highlights acquisition speculation regarding Monzo, though the company has denied pursuing a transaction. Technical indicators show a bullish moving average signal but neutral oscillators, with RSI suggesting potential overbought conditions.

The outlook remains positive given NU's expanding customer base and profitability trajectory, with analyst consensus favoring Buy ratings (56.5%) and a $16.53 price target representing 6% upside. Key risks include credit quality concerns from rising delinquencies and the stock's premium valuation multiples. The company's operational efficiency and Latin American expansion provide growth catalysts, though investors should monitor execution against earnings expectations.